OA21083A - Treatment and prevention of preeclampsia. - Google Patents
Treatment and prevention of preeclampsia. Download PDFInfo
- Publication number
- OA21083A OA21083A OA1202000311 OA21083A OA 21083 A OA21083 A OA 21083A OA 1202000311 OA1202000311 OA 1202000311 OA 21083 A OA21083 A OA 21083A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- eclampsia
- use according
- inhibitor
- esterase inhibitor
- Prior art date
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 107
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 56
- 210000002700 urine Anatomy 0.000 claims description 30
- 238000005259 measurement Methods 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 125000005629 sialic acid group Chemical group 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 229940122601 Esterase inhibitor Drugs 0.000 claims description 4
- 239000002329 esterase inhibitor Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 108010028774 Complement C1 Proteins 0.000 claims description 3
- 102100025406 Complement C1s subcomponent Human genes 0.000 claims description 3
- 102000000429 Factor XII Human genes 0.000 claims description 3
- 108010080865 Factor XII Proteins 0.000 claims description 3
- 102000001399 Kallikrein Human genes 0.000 claims description 3
- 108060005987 Kallikrein Proteins 0.000 claims description 3
- 241000283953 Lagomorpha Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 125000000837 carbohydrate group Chemical class 0.000 claims description 3
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- 229940110272 plasma derived c1-inhibitor Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 20
- 230000004913 activation Effects 0.000 description 12
- 108700005721 conestat alfa Proteins 0.000 description 10
- 229960005020 conestat alfa Drugs 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 102000016550 Complement Factor H Human genes 0.000 description 8
- 108010053085 Complement Factor H Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 3
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 102000020286 Pyruvate Dehydrogenase (Lipoamide)-Phosphatase Human genes 0.000 description 3
- 108010040259 Pyruvate Dehydrogenase (Lipoamide)-Phosphatase Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000557 podocyte Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003152 bradykinin antagonist Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 208000009206 Abruptio Placentae Diseases 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ZULNQPCZALKHMF-UHFFFAOYSA-N IPG-A Natural products [NH3+]C1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C2OP([O-])(=O)OC21 ZULNQPCZALKHMF-UHFFFAOYSA-N 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 208000019547 Placental disease Diseases 0.000 description 1
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 229940088950 c1 esterase inhibitor (human) Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 230000008347 uteroplacental blood flow Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Abstract
The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia.
Description
Treatment and prévention of pre-eclampsia
Field of the invention
The present invention relates to the field of medicine, specifically to the prévention and treatment 5 of pre-eclampsia.
Background of the invention
Pre-eclampsia (PE) is a placental disease [1] characterized by insufficiency of the uteroplacental circulation [2], and which affects 10-12% of ail pregnancies and is a major factor in the périnatal 10 mortality rate. Pre-eclampsia is a severe complication of human pregnancy characterized by development of hypertension and proteinuria and it affects maternai and foetal morbidity and mortality worldwide [3], In developed countries, pre-eclampsia has been reported to complicate 1 to 4% of ail pregnancies [3] while in developing countries the prevalence can be as high as 17% [4], In developing countries hypertensive disorders of pregnancy heavily contribute to al! maternai 15 and foetal deaths [5], There is evidence that one or more placental-derived factors are released into the maternai circulation which either directly or indirectly cause maternai endothélial dysfunction and ensuing maternai problems with activation of the clotting system increased vascular permeability and ischemia in maternai organs secondary to vasoconstriction [6], It has been postulated that administration of a P-type IPG antagonist could be effective in the treatment 20 of pre-eclampsia (WO9810791). To date however, there is no treatment that is satisfactorily effective for the prévention or treatment of pre-eclampsia except for delivery of the baby.
Summary of the invention
The invention provides for a compound for use in the prévention of pre-eclampsia in a subject at 25 risk of pre-eclampsia or for use in the treatment of a subject suffering from pre-eclampsia, wherein said compound is a complément inhibitor.
The invention further provides for a method of prévention of pre-eclampsia in a subject at risk ot pre-eclampsia or a method of treatment of a subject suffering from pre-eclampsia, comprising administration of a complément inhibitor to the subject.
The invention further provides for the use of a complément inhibitor for the prévention of preeclampsia in a subject at risk of pre-eclampsia or for the treatment of a subject suffering from preeclampsia, comprising administration of a complément inhibitor to the subject.
Detailed description ofthe invention
The inventors arrived at the surprising finding that inhibition of the complément system can be effective for the prévention and treatment of pre-eclampsia.
Accordingly, in a first aspect, the invention provides for a compound for use in the prévention of pre-eclampsia in a subject at risk of pre-eclampsia or for use in the treatment of a subject suffering from pre-eclampsia, wherein said compound is a complément inhibitor. Herein, the 40 compound for use is referred to as the compound according to the invention. In ail embodiments of the invention, a complément inhibitor is construed as any compound that is capable of inhibiting the complément pathway to at least some extent, such as one step within the pathway. Preeclampsia is construed herein as defined in the background section here above. The compound according to the invention may be any compound, it may be a small molécule, a protein, peptide, an antibody, an enzyme, an enzyme inhibitor such as a protease inhibitor or a chelator. Prévention of pre-eclampsia is herein construed as a delay of the onset of pre-eclampsia and/or a signifîcant réduction of pre-eclampsia when the onset of pre-eclampsia occurs in a person at risk of pre-eclampsia. Treatment of pre-eclampsia is herein construed as a signifîcant réduction of preeclampsia in a subject suffering from pre-eclampsia.
In the embodiments of the invention, the compound for use according to the invention, the complément inhibitor, can be: an antibody, an agent inhibiting Factor XII activity, an agent inhibiting Kallikrein activity, a bradykinin receptor antagonist or blocker and/or an agent inhibiting C1 esterase activity. In the embodiments of the invention, the complément inhibitor can be a C1 esterase inhibitor. The C1 esterase inhibitor may be any C1 esterase inhibitor known to the person skilled in the art. In an embodiment, the C1 esterase inhibitor is an antibody directed against (human) C1 inhibitor. In the embodiments of the invention, the C1 esterase inhibitor can be a plasma-derived C1 esterase inhibitor. In the embodiments of the invention, the C1 esterase inhibitor can be a recombinant C1 esterase inhibitor, preferably a C1 esterase inhibitor having an amino acid sequence that is substantially identîcal to the amino acid sequence of human plasmaderived C1 esterase inhibitor. The recombinant C1 esterase inhibitor can be any recombinant C1 esterase inhibitor known the person skilled in the art. It may be produced recombinantly in microbial cells, such as tissue culture cells. The tissue culture cell can be a mammalian tissue culture cell, such as a Chinese Hamster Ovarian (CHO) cell or a human tissue culture cell (see e.g. WO2016/081889, which is herein incorporated by reference). The recombinant C1 esterase inhibitor can be produced in transgenic animais, such as in a transgenic non-human mammal, preferably a mouse, goat, bovine, sheep, porcine or an animal from the order Lagomorpha, such as a Leporadae, includîng a rabbit. In an embodiment, the recombinant C1 esterase inhibitor is one produced according to the methods in WO01/57079, which is herein incorporated by reference.
In the embodiments of the invention, the C1 esterase inhibitor can be a modified C1 esterase inhibitor as compared to human plasma-derived C1 esterase inhibitor. It can be modified to modulate the plasma half-life ofthe C1 esterase inhibitor. A spécifie modified C1 esterase inhibitor is conjugated to enhance the plasma half-life. An exemplary conjugated C1 esterase inhibitor to enhance half-life is a conjugated C1 esterase inhibitor according to WO2017/176798, which is herein incorporated by reference, such as a polysialic acid (PSA)-conjugated C1 esterase inhibitor, more preferably a polyethylene glycol (PEG)-conjugated C1 esterase inhibitor. The modification ofthe C1 esterase inhibitor can be a modified carbohydrate structure as compared to human plasma-derived C1 esterase inhibitor. A spécifie modified C1 esterase inhibitor has a reduced level of terminal sialic acid residues as compared to plasma derived 01 esterase inhibitor, wherein said reduced level of terminal sialic acid residues may resuit in a réduction of plasma half-life to less than 6 hours. A spécifie C1 esterase inhibitor having a reduced level of terminal sialic acid residues as compared to plasma derived C1 esterase inhibitor is a C1 esterase inhibitor according to WO01/57079, WO2004/100982 and WO2007/073186 which are herein incorporated by reference.
The compound according to the invention can be administered as such and can be administered comprised in a pharmaceutical composition. The pharmaceutical composition can comprise a pharmaceutically accepted excipient and/or can comprise a further pharmaceutical compound. The compound according to the invention may be administered by any means known to the person skilled in the art, such as but not limited, to intravenous, transdermal and subeutaneous administration. Intravenous administration is extensively described in WO01/57079, WO2004/100982 and WO2007/073186. Subeutaneous administration is preferably performed as in WO2014/145519, US9616111B2 and EP2968434B1, which are herein incorporated by reference.
In the embodiments of the invention, the compound according to the invention can be administered to the subject at least once a month, or at least once a week. The compound according to the invention can be administered at least once, twice, three or four times a month, at least once, twice, three, four, five, six or seven times a week or can be administered, every other day, daily, or twice a day.
When the compound according to the invention is a C1 esterase inhibitor, the compound can be administered in a dose ranging from 25 units/kg body weight to 100 units/kg body weight per administration, preferably ranging from 50 units/kg body weight to 100 units/kg body weight per administration. Per administration the dose can be 25 units/kg body weight, 50 units/kg body weight, 100 units/kg body weight. The total dose per administration can be 1000 units, 1400 units, 1500 units, 2000 units, 2100 units, 2800 units, 3000 units, 3500 units, 4000 units, 4200 units, 4500 units, 4900 units, 5000 units, 5600 units, 6000 units, 6300 units, 7000 units, 7500 units, 8000 units, 8400 units or 9000 units C1 inhibitor.
In the embodiments of the invention, the subject can be a prégnant mammal, preferably a prégnant human.
In the embodiments of the invention, the subject suffering from pre-eclampsia can be suffering from early-onset pre-eclampsia (<34 weeks gestational âge) or from late-onset pre-eclampsia (>34 weeks gestational âge).
The diagnosis of pre-eclampsia or of a risk of pre-eclampsia can be made by any means and assay known to the person skilled in the art. The diagnosis may e.g. be made by assessing whether there is occurrence of hypertension en proteinuria. The diagnosis can be made by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
Accordingly, the invention provides for a compound for use according to the invention, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine. In an embodiment, the invention provides for a compound for use according to the invention, wherein the subject is diagnosed with of being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine. Preferably, the Ptype inositolphosphoglycans (P-type IPG) is placenta-derived P-type inositolphosphoglycans (Ptype IPG). In the embodiments of the invention, the measurement can be performed by any means known to the person skilled in the art, such as by using the method as described in WO9810791, which is herein incorporated by reference. Preferably, the measurement is performed according to experiments A-1, A-2, A-5 and A-6 of WO9810791. For reference, the here mentioned parts of WO9810791 are copied here below.
The activity of P- and A-type IPGs in urine and placental extracts were studied using spécifie bioassay procedures. IPG P-type was determined using the activation of PDH phosphatase [7], The PDH complex and PDH phosphatase (metal-dependent form) were prepared from beef heart as described by Lilley et al. [7] and the assay of the activation of the phosphatase was performed by the spectrophotometric variant of the two-stage system described by these authors. This assay is consîdered to be a characteristic feature of IPG P-type (see Lamer et al. [8]). IPG A-type was determined by the stimulation of lipogenesis as measured by the incorporation of [U14C] glucose into the Hpids of adipocytes isolated from epididymal fat pads by the method of Rodbell [9]. A high degree of specificity for IPG A-type was found for this bioassay.
A straight line relationship between added IPGs and the stimulation of PDH phosphatase activity (IPG P-type) and lipogenesis in intact adipocytes (IPG A-type) was obtained; this relationship held at least up to a stimulation of -1-250%. These observations provided a basis for a unit to be defined and used for the purpose of comparison of yields of IPGs from different tissues and urine samples. Linearity between IPG added and the percentage change in response, has been observed by others (see Lilley et al. [7] and Newman et al. [10]), although Asplin et al. [11] did not show linearity in their study on IPGs in human urine from normal and diabetic subjects, an effect which was particularly marked with the IPG A-type (pH 1.3 fraction).
Extraction of IPG P-type and IPG-A type from urine was performed as described by Asplin et. al. [11], The final fractions were freeze dried and stored at - 20°C. For use, the IPG fractions were resuspended in water, immediately before assay, so that 10μΙ of redissolved IPG corresponded to 10ml urine.
In view of the possibility that high, and varying, amounts of IPGs might be excreted in the different groups of prégnant and pre-eclamptic subjects, and in order to ensure that the capacity of the resin was well in excess of the load applied, preliminary test runs were made to determine the optimal ratio of resin to starting urine volume. Linearity of recovery was obtained up to 100ml urine per 18g resin. In the present study, the ratio of 30ml urine to 18g resin was maintained to allow for variation in IPG content.
Expression of results: A unit of IPG is defined as the amount causing a 50% activation in the basal level of the test system.
The yield of IPGS in urine is given on three different bases:
(i) Percentage stimulation of the test system by 10μΙ final urine extract (Col 1), allowing direct comparison with data of Asplin et. al. [11] (ii) Units of IPG per 1 mmol créatinine.
(iii) Units of IPG found in a sample of a 24 hour collection or urine; i.e.: the total daily output at that stage of gestation.
In a second aspect, the invention provides for a method of prévention of pre-eclampsia in a subject at risk of pre-eclampsia and a method of treatment of a subject suffering from preeclampsia, comprising administration of a complément inhibitor to the subject. The features of this aspect of the invention can be those of the first aspect of the invention.
In this aspect of the invention, the subject can be diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine. In the embodiments of the invention, the measurement can be performed using the method as described in WO9810791, which is herein incorporated by reference. Preferably, the measurement is performed according to experiments A-1, A-2, A-5 and
A-6 ofWO9810791.
In a third aspect, the invention provides for the use of a complément inhibitor for the prévention of pre-eclampsia in a subject at risk of pre-eclampsia and for the treatment of a subject suffering from pre-eclampsia, comprising administration of a complément inhibitor to the subject. The features of this aspect of the invention can be those of the first and second aspect of the invention. In this aspect of the invention, the subject can be diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine. In the embodiments of the invention, the measurement can be performed using the method as described in WO9810791, which is herein incorporated by reference. Preferably, the measurement is performed according to experiments A-1, A-2, A-5 and A-6 of WO9810791.
In a fourth aspect, the invention provides for a complément inhibitor for the manufacture of a médicament for the prévention of pre-eclampsia in a subject at risk of pre-eclampsia and for the treatment of a subject suffering from pre-eclampsia, comprising administration of the complément inhibitor to the subject. The features of this aspect of the invention can be those of the first, second and third aspect of the invention. In this aspect of the invention, the subject can be diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placentaderived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine. In the embodiments of the invention, the measurement can be performed using the method as described in WO9810791, which is herein incorporated by reference. Preferably, the measurement is performed according to experiments A-1, A-2, A-5 and A-6 of WO9810791.
Unless otherwise indicated each embodiment as described herein may be combined with another embodiment as described herein.
Définitions
In this document and in its claims, the verb to comprise and its conjugations is used in its nonlimiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition the verb “to consist” may be replaced by to consist essentially of” meaning that a product or a composition or a nucleic acid molécule or a peptide or polypeptide of a nucleic acid construct or vector or cell as defined herein may comprise additional component(s) than the ones specifically identified; said additional component(s) not altering the unique characteristic of the invention. In addition, reference to an element by the indefinite article a or an does not exclude the possibility that more than one of the éléments is present, unless the context clearly requires that there be one and only one of the éléments. The indefinite article a or an thus usually means at least one.
Herein, one unit (U) of C1 esterase inhibitor is the amount of C1 esterase inhibitor present in 1 milliliter of human plasma. One such unit corresponds to approximately 275 microgram plasmaderived C1 esterase inhibitor.
Ail patent and literature references cited in the present spécification are hereby incorporated by reference in their entirety.
Embodiments ofthe invention
1. A compound for use in the prévention of pre-eclampsia in a subject at risk of pre-eclampsia or for use in the treatment of a subject suffering from pre-eclampsia, wherein said compound is a complément inhibitor.
2. A compound for use according to embodiment 1, wherein the complément inhibitor is: an antibody, an agent inhibiting Factor XII activity, an agent inhibiting Kallikrein activity, an agent inhibiting bradykinin activity and/or an agent inhibiting C1 esterase activity.
3. A compound for use according to embodiment 1 or 2, wherein the complément inhibitor is a C1 esterase inhibitor.
4. A compound for use according to embodiment 4, wherein the C1 esterase inhibitor is an antibody.
5. A compound for use according to embodiment 4, wherein the C1 esterase inhibitor is a plasma-derived C1 esterase inhibitor.
6. A compound for use according to embodiment 4, wherein the C1 esterase inhibitor is a recombinant C1 esterase inhibitor, such as a C1 esterase inhibitor having an amino acid sequence that is substantially identîcal to the amino acid sequence of human plasmaderived C1 esterase inhibitor.
7. A compound for use according to embodiment 4, wherein the recombinant esterase inhibitor is produced in a transgenic non-human mammal, such as a mouse, goat, bovine, sheep, porcine or an animal from the order Lagomorpha, such as a Leporadae, including a rabbit.
8. A compound for use according to any one of embodiments 5-7, wherein the Cl esterase inhibitor has a modîfied carbohydrate structure as compared to human plasma-derived C1 esterase inhibitor.
9. A compound for use according to embodiment 8, wherein the C1 esterase inhibitor has a reduced level of terminal sialic acid residues as compared to plasma derived C1 inhibitor, wherein said reduced level of terminal sialic acid residues preferably results in a plasma half-life of less than 6 hours.
10. A compound for use according to any one of the preceding embodiments, wherein the compound is adminîstered to the subject at least once a month, or at least once a week.
11. A compound for use according to any one of embodiments 5-10, wherein the compound is adminîstered in a dose ranging from 25 units/kg body weight to 100 units/kg body weight per administration, or ranging from 50 units/kg body weight to 100 units/kg body weight per administration.
12. A compound for use according to any one of the preceding embodiments, wherein the subject is a prégnant mammal, preferably a prégnant human.
13. A compound for use according to any of the preceding embodiments, wherein the subject suffering from pre-eclampsia is suffering from early-onset pre-eclampsia (<34 weeks gestational âge) or from late-onset pre-eclampsia (>34 weeks gestational âge).
14. A compound for use according to any of the preceding embodiments, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, preferably in blood or urine.
15. A compound for use according to any of the preceding embodiments, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, preferably in blood or urine.
16. A compound for use according to embodiment 14 or 15, wherein the measurement is performed using the method as described in WO9810791.
17. A method of prévention of pre-eclampsia in a subject at risk of pre-eclampsia or a method of treatment of a subject suffering from pre-eclampsia, comprising administration of a complément inhibitor to the subject.
18. A method of prévention of pre-eclampsia in a subject at risk of pre-eclampsia or a method of treatment of a subject suffering from pre-eclampsia according to embodiment 17, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositoiphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
19. A method of prévention of pre-eclampsia in a subject at risk of pre-eclampsia or a method of treatment of a subject suffering from pre-eclampsia according to embodiment 17 or 18, wherein the measurement is performed using the method as described in WO9810791.
20. Use of a complément inhibitor for the prévention of pre-eclampsia in a subject at risk of preeclampsia or for the treatment of a subject suffering from pre-eclampsia, comprising administration of a complément inhibitor to the subject.
21. Use according to embodiment 20, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositoiphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
22. Use according to embodiment 20 or 21, wherein the measurement is performed using the method as described in WO9810791.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Examples
Example 1
C1 esterase inhibitor from transgenic rabbits prepared as in WO01/57079 (Ruconest™, Pharming, the Netherlands) is administered on daily basis in a 50 units/kg bodyweight dose to prégnant human subjects suffering from early-onset pre-eclampsia (<34 weeks gestational âge) or from late-onset pre-eclampsia (>34 weeks gestational âge). A control group receives no treatment except for the State of the art hospitalization. On average, the treated groups demonstrate significant positive effects of the treatment as demonstrated by lower blood pressure and lower proteinuria.
Example 2
C1 esterase inhibitor from transgenic rabbits prepared as in WO01/57079 (Ruconest™, Pharming, the Netherlands) is administered on daily basis in a 50 units/kg bodyweight dose to prégnant human subjects at risk of pre-eclampsia (>34 weeks gestational âge). A control group receives no treatment except for the State of the art hospitalization. On average, the treated group demonstrates significant positive effects of the treatment as demonstrated by no or later onset of pre-eclampsia and lower blood pressure and lower proteinuria when pre-eclampsia does occur.
Example 3
SYNOPSIS PRE-ECLAMPSIA CLINICAL STUDY
Study Title: A Phase l/ll, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor (conestat alfa) in Patients with preeclampsia.
Study Phase: Phase l/ll, proof of concept study
Number of Patients: Up to 30 patients can be enrolled. Recruitment will stop once 20 patients completed the treatment period or 30 patients hâve been enrolled whichever cornes first. Already enrolled patients will complété the study as per protocol.
Rationale:
The current trial intends to evaluate the tolerability and safety of recombinant human C1 esterase inhibitor (rhCIINH) conestat alfa - in the patient with pre-eclampsia and further explore the efficacy of such a treatment.
Objectives:
Primary:
To evaluate the tolerability and safety of the treatment with rhCIINH (conestat alfa) on top of Standard Care, for patients with pre-eclampsia.
Secondary:
To evaluate the efficacy of treatment with rhCIINH (conestat alfa) on top of Standard Care, for patients with pre-eclampsia.
Exploratory:
To further characterize the clinical safety of treatment with rhCIINH (conestat alfa) on top of Standard Care, for patients with pre-eclampsia by measuring évolution of laboratory parameters like platelet count, LDH, ALAT, ASAT, Kreat, Hb, Ht, urine protein, urine kreatinine,
To îdentify changes in biomarkers of pre-eclampsia (PIGF, VEGF, sFlt-1, IPG, podocytes level) following rhCIINH (conestat alfa) treatment.
To analyze complément activation and other immune characteristics in the mother’s blood and urine (C4, C1q, C5b and factor H) and in the placenta and cord blood (C4, C1q, C5b and factor H, leucocyte count and FACS analysis)
To evaluate immune system in the baby’s blood after birth by measuring complément activation (C4, C1q, C5b, factor H) leucocyte count and performing a FACS analysis.
To evaluate plasma pharmacokinetic profile of rhCIINH (conestat alfa) in prégnant women.
Study design:
This is an open label, proof of concept study on the treatment with rhCIINH (conestat alfa) of patients with pre-eclampsia between 27-34 weeks gestation. The study will consist of a screening visit, an enrolment visit, a treatment period and a follow-up period.
Study population:
Up to 30 prégnant women between 27-34 weeks of gestation referred to hospital care centers for management of their pregnancy with pre-eclampsia, fulfilling the inclusion criteria, are eligible for participation in the study:
Intervention:
Twice weekly open label intravenous treatment with conestat alfa at a dose of 50 units/kg (based on body weight at start of treatment) up to a maximum of 4200 units on top of Standard Care.
Main study parameters/endpoints:
Primary endpoint:
• Incidence and severity of adverse events • Number and percentage of patients who discontinue investigational product or withdraw from the study
Secondarv endpoints:
• Time from start of conestat alfa to day of delivery • Proportion of patients reaching gestation week 37
Explorative endpoints:
Mother:
• Biochemistry and hematology parameters over time, including safety parameters like platelet count, LDH, ALAT, ASAT, créatinine, Hb, Ht.
• Urine protein and créatinine level • Number of women who develop HELLP syndrome, eclampsia.
• Number of women with placental abruption • Plasma concentration of C1 INH - pharmacokinetic profile analysis • Biomarkers in blood sFlt-1, VEGF and PIGF • Biomarkers in urine: IPG and podocyte levels • Gestational âge at birth • Incidence of admission to a néonatal intensive care unit as applicable • Time spent in the néonatal intensive care unit • Normalization of uterine Doppler flow profiles • Normalization of Doppler profiles of the Umbilical artery and/or médial cérébral artery • Quantification of complément activation in placental tissue (C1q) • Quantification of complément activation in maternai blood and urine samples (C4, C1q, C5b, factor H) • Proportion of patients reaching gestation week 34, or 30
Baby:
• Birthweight • Delivery of healthy baby, defined as: a term baby, normal weight (= per country/part of the world), normal APGAR score, no congénital abnormalities, normal head circumference • Incidence of néonatal:
o Necrotizing enterocolitis o Respîratory distress syndrome, o Cérébral hemorrhage, o Grade 3-4 intraventricular hemorrhage, o Bronchopulmonary dysplasia • Normal Immune system in the baby’s blood and cord blood by measuring complément activation (C4, C1q, C5b, factor H), leucocyte count and a performing a FACS analysis • Normal pédiatrie echocardiography after delivery
Efficacy analyses:
Efficacy analyses will be performed for the following:
• Time from start of treatment to delivery • Patients reaching gestation week 37
Pharmacokinetic profile Analyses
The mean plasma concentrations of C1INH over time will be plotted and analyzed visually.
Biomarkers for PE • Biomarkers for pre-eclampsia (sFlt-1, PIGF, VEGF, podocytes levels and IPG) • Quantification of complément activation in placental tissue and cord blood (C4, C1q. C5b, factor H) • Quantification of complément activation in maternai blood and urine samples (C4, C1q. C5b, factor H) • Quantification of complément activation in baby’s blood (C4, C1q. C5b, factor H) at 3 months follow up visit
Référencés
1. Redman, C.W.G., 1991. Pre-eclampsia and the placenta. Placenta, 12(4), pp.301-308.
2. Robertson, W.B., Brosens, I. and Dixon, H.G., 1967. The pathological response ofthe vessels ofthe placental bed to hypertensive pregnancy. The Journal of Pathology, 93(2), pp.581-592.
3. Steegers, E.A., von Dadelszen, P., Duvekot, J.J. and Pijnenborg, R., 2010. Pre-eclampsia. The Lancet, 376(9741), pp.631-644.
4. Osungbade, K.O. and Ige, O.K., 2011. Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. Journal of pregnancy, 2011.
5. The world health report 2005 - make every mother and child count. WHO, Geneva. Available at: www.who.int/whr/2005/en/.
6. Romero, G., 1991. Inositolglycans and cellular signalling. Cell biology international reports, 15(9), pp.827-852.
7. Lilley, K., Zhang, C., Villar-Palasi, C., Larner, J. and Huang, L., 1992. Insulin mediator stimulation of pyruvate dehydrogenase phosphatases. Archives of biochemistry and biophysics, 296(1), pp. 170-174.
8. Larner, J., Huang, L.C., Suzuki, S., Tang, G., Zhang, C., Schwartz, C.F.W., Romero, G., Luttrell, L. and Kennington, A.S., 1989. Insulin mediators and the control of pyruvate dehydrogenase complex. Annals of the New York Academy of Sciences, 573(1), pp.297-305.
9. Rodbell, M., 1964. The metabolism of isolated fat cells. Comprehensive Physiology.
10. Newman, J., Armstrong, J.M. and Bomstein, J., 1985. Assay of insulin mediator activity with soluble pyruvate dehydrogenase phosphatase. Endocrinology, 116(5), pp. 1912-1919.
11. Asplin, L, Galasko, G. and Larner, J., 1993. Chiro-inositol deficiency and insulin résistance: a comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proceedings of the National Academy of Sciences, 90(13), pp.5924-5928.
Claims (15)
1. A compound for use in the prévention of pre-eclampsia in a subject at risk of pre-eclampsia or for use in the treatment of a subject suffering from pre-eclampsia, wherein said compound is a complément inhibitor.
2. A compound for use according to claim 1, wherein the complément inhibitor is: an antibody, an agent inhibiting Factor XII activity, an agent inhibiting Kallikrein activity, an agent inhibiting bradykinin activity and/or an agent inhibiting C1 esterase activity.
3. A compound for use according to claim 1 or 2, wherein the complément inhibitor is a C1 esterase inhibitor.
4. A compound for use according to claim 4, wherein the C1 esterase inhibitor is an antibody.
5. A compound for use according to claim 4, wherein the C1 esterase inhibitor is a plasmaderived C1 esterase inhibitor.
6. A compound for use according to claim 4, wherein the C1 esterase inhibitor is a recombinant C1 esterase inhibitor, such as a C1 esterase inhibitor having an amino acid sequence that is substantially identical to the amino acid sequence of human plasmaderived C1 esterase inhibitor.
7. A compound for use according to claim 4, wherein the recombinant esterase inhibitor is produced in a transgenic non-human mammal, such as a mouse, goat, bovine, sheep, porcine or an animal from the order Lagomorpha, such as a Leporadae, including a rabbit.
8. A compound for use according to any one of claims 5-7, wherein the C1 esterase inhibitor has a modified carbohydrate structure as compared to human plasma-derived C1 esterase inhibitor.
9. A compound for use according to claim 8, wherein the C1 esterase inhibitor has a reduced level of terminal sialic acid residues as compared to plasma derived C1 inhibitor, wherein said reduced level of terminal sialic acid residues preferably results in a plasma half-life of less than 6 hours.
10. A compound for use according to any one of the preceding claims, wherein the compound is administered to the subject at least once a month, or at least once a week.
14
11. A compound for use according to any one of claims 5-10, wherein the compound is administered in a dose ranging from 25 units/kg body weight to 100 units/kg body weight per administration, or ranging from 50 units/kg body weight to 100 units/kg body weight per administration.
12. A compound for use according to any one of the preceding claims, wherein the subject is a prégnant mammal, preferably a prégnant human.
13. A compound for use according to any of the preceding claims, wherein the subject suffering from pre-eclampsia is suffering from early-onset pre-eclampsia (<34 weeks gestational âge) or from late-onset pre-eclampsia (>34 weeks gestational âge).
14. A compound for use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
15. A compound for use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placentaderived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18159064.7 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA21083A true OA21083A (en) | 2023-11-13 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Suarez et al. | Renal disorders in pregnancy: core curriculum 2019 | |
Fakhouri et al. | Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group | |
Frimat et al. | Renal cortical necrosis in postpartum hemorrhage: a case series | |
Scully et al. | Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. | |
Martin Jr et al. | Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006 | |
Zhou et al. | Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function | |
US20140219984A1 (en) | The Use of Alkaline Phosphatase for Preserving Renal Function | |
Mudjari et al. | Management of hypertension in pregnancy | |
EP3758739B1 (en) | Treatment and prevention of pre-eclampsia | |
Ramadan et al. | HELLP syndrome, thrombotic thrombocytopenic purpura or both: appraising the complex association and proposing a stepwise practical plan for differential diagnosis | |
Sayad et al. | Pregnancy, preeclampsia, and covid-19: susceptibility and mechanisms: A Review Study | |
Ghazanfar et al. | D-dimer as a potential blood biomarker for disease activity and treatment response in chronic urticaria: a focused review | |
Nortier et al. | Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring | |
Yagi et al. | Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency | |
Kenny et al. | Maternal pathophysiology in pre-eclampsia | |
Gabarre et al. | Inverted takotsubo syndrome with HELLP Syndrome: a case report | |
OA21083A (en) | Treatment and prevention of preeclampsia. | |
Hunley et al. | Hypertension in the pregnant teenager | |
Miranda et al. | Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial | |
Park | The antiphospholipid syndrome | |
Dap et al. | Thrombotic thrombocytopenic purpura and severe preeclampsia: A clinical overlap during pregnancy and a possible coexistence | |
Sahay | Acute kidney injury in pregnancy | |
RU2333497C1 (en) | Method predicting chronic renal insufficiency at patients with postcapillarotoxic glomerulonephritis | |
Bates | Thrombophilia in pregnancy | |
FRIKHA et al. | Acquired Hemophilia A in the South of Tunisia: A Single Center Study |